Serum ceruloplasmin can predict liver fibrosis in hepatitis B virus-infected patients

Table 1 Demographic characteristics and clinical features in our patient cohort

		ALL (n = 275)	Training group (n = 138)	Validation group (n = 137)	P value
Age (yr)		40.25 ± 9.65	40.90 ± 9.90	39.61 ± 9.37	0.267
Gender	Male	194 (70.5%)	101 (73.2%)	93 (67.9%)	0.335
	Female	81 (29.5%)	37 (26.8%)	44 (32.1%)
CP (mg/L)		213.01 ± 43.28	212.72 ± 42.68	213.29 ± 44.03	0.914
Total bilirubin (μmol/L)		13.51± 7.16	13.31 ± 6.46	13.71 ± 7.80	0.652
Albumin (g/L)		42.84 ± 3.68	42.93 ± 3.74	42.75 ± 3.63	0.692
Globulin (g/L)		28.19 ± 18.49	29.43 ± 6.04	27.01 ± 4.28	0.291
ALT (IU/L)		29.56 ± 9.86	29.65 ± 9.69	29.46 ± 10.07	0.872
AST (IU/L)		26.91 ± 7.17	26.71 ± 7.19	27.11 ± 7.16	0.645
GGT (IU/L)		29.48 ± 21.87	29.23 ± 24.34	29.71 ± 19.28	0.860
TCHO (mmol/L)		4.69 ± 0.89	4.61 ± 0.75	4.77 ± 1.00	0.149
TG (mmol/L)		1.15 ± 0.68	1.25 ± 0.80	1.05 ± 0.50	0.113
CHE (IU/mL)		8215.20 ± 2312.22	8409.96 ± 2358.01	8027.75 ± 2260.29	0.182
WBC (109/L)		5.68 ± 1.48	5.74 ± 1.48	5.62 ± 1.49	0.509
PLT (109/L)		191.96 ± 51.77	193.78 ± 51.91	190.11 ± 51.76	0.558
HBsAg (Log IU/mL)		3.95 ± 0.95	3.89 ± 0.99	3.40 ± 0.90	0.346
HBV-DNA (Log IU/mL)		5.13 ± 2.02	5.08 ± 2.01	5.19 ± 2.03	0.666
PT (s)		12.11 ± 2.31	12.04 ± 2.56	12.18 ± 2.04	0.626
INR		1.00 ± 0.19	0.99 ± 0.21	1.01 ± 0.17	0.662
Fibrosis stage, n (%)					0.670
F0		19 (6.9)	12 (8.7)	7 (5.1)
F1		106 (38.5)	52 (37.7)	54 (39.4)
F2		57 (20.7)	26 (18.8)	31 (22.6)
F3		40 (14.5)	19 (13.8)	21 (15.3)
F4		53 (19.3)	29 (21.0)	24 (17.5)

CP: Ceruloplasmin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Gamma glutamyl transpeptidase; TCHO: Total cholesterol; TG: Triglyceride; CHE: Cholinesterase; WBC: White blood cell count; PLT: Platelet count; HBV: Hepatitis B virus; PT: Prothrombin time; INR: International normalized ratio.